A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults

References

• WHO. HIV key facts. cited 2023 Jul 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids
   Google Scholar
• UNAIDS. Global HIV & AIDS statistics - fact sheet. 19 Jul 2023. [cited 2023 Jul 19]. Available from: https://www.unaids.org/en/resources/fact-sheet
   Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355. doi: 10.1371/journal.pone.0081355
   PubMed Web of Science ®Google Scholar
• May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28(8):1193–1202. doi: 10.1097/QAD.0000000000000243
   PubMed Web of Science ®Google Scholar
• Insight Start Study Group. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373(9):795–807.
   PubMed Web of Science ®Google Scholar
• EACS Guidelines, Version 11.1 – October 2022. [cited 2023 Jul 19]. Available from: https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf
   Google Scholar
• Waters L, Winston A, Reeves I, et al. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. HIV Med. 2022;23(Suppl 5):3–115. doi: 10.1111/hiv.13446
   PubMedGoogle Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. [cited 2023 Jul 19]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv
   Google Scholar
• Anstett K, Brenner B, Mesplede T, et al. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14(1):36. doi: 10.1186/s12977-017-0360-7
   PubMedGoogle Scholar
• Mbhele N, Chimukangara B, Gordon M. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents. 2021;57(5):106343. doi: 10.1016/j.ijantimicag.2021.106343
   PubMed Web of Science ®Google Scholar
• Kelly SG, Masters MC, Taiwo BO. Initial antiretroviral therapy in an integrase inhibitor era: can we do better? Infect Dis Clin North Am. 2019;33(3):681–692. doi: 10.1016/j.idc.2019.05.003
   PubMed Web of Science ®Google Scholar
• Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clinical Infectious Diseases. 2011;53(12):1265–1270. doi: 10.1093/cid/cir684
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Brochot A, Tomaka FL, et al. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir. J Antimicrob Chemother. 2014;69(10):2591–2605. doi: 10.1093/jac/dku193
   PubMed Web of Science ®Google Scholar
• Weber IT, Kneller DW, Wong-Sam A. Highly resistant HIV-1 proteases and strategies for their inhibition. Future Med Chem. 2015;7(8):1023–1038. doi: 10.4155/fmc.15.44
   PubMed Web of Science ®Google Scholar
• Lascar RM, Benn P. Role of darunavir in the management of HIV infection. HIV AIDS (Auckl). 2009;1:31–39.
   PubMedGoogle Scholar
• Prezista® summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/prezista-epar-product-information_en.pdf
   Google Scholar
• Sekar V, De La Rosa G, Van de Casteele T, et al. Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial. J Int AIDS Soc. 2010;13(Suppl 4):185. doi: 10.1186/1758-2652-13-S4-P185
   Google Scholar
• Samuels ER, Sevrioukova IF. Interaction of CYP3A4 with rationally designed ritonavir analogues: impact of steric constraints imposed on the heme-ligating group and the end-pyridine attachment. Int J Mol Sci. 2022;23(13):7291. doi: 10.3390/ijms23137291
   PubMed Web of Science ®Google Scholar
• Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1(5):209–213. doi: 10.1021/ml1000257
   PubMed Web of Science ®Google Scholar
• Callebaut C, Tsai L, Stray K, et al. Biological profiling of GS-9350, a novel pharmacoenhancer that lacks anti-HIV activity and exhibits low potential for metabolic adverse effects in vitro. Antivir Res. 2010;86(1):A31. doi: 10.1016/j.antiviral.2010.02.365
   Web of Science ®Google Scholar
• Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87(3):322–329. doi: 10.1038/clpt.2009.228
   PubMed Web of Science ®Google Scholar
• Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755–1758. doi: 10.1093/jac/dkw032
   PubMed Web of Science ®Google Scholar
• Crutchley RD, Guduru RC, Cheng AM. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV/AIDS-Res Palliative Care. 2016;8:47–65. doi: 10.2147/HIV.S99063
   Google Scholar
• Emtriva® summary of product characteristics. [cited 2023 Jul 19]. Available from: https://www.ema.europa.eu/en/documents/product-information/emtriva-epar-product-information_en.pdf
   Google Scholar
• Valade E, Tréluyer JM, Bouazza N, et al. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother. 2014;58(4):2256–2261. doi: 10.1128/AAC.02058-13
   PubMed Web of Science ®Google Scholar
• Emtriva® full prescribing information. [cited 2023 Jul 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021500s029lbl.pdf
   Google Scholar
• Markowitz M, Zolopa A, Squires K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014;69(5):1362–1369. doi: 10.1093/jac/dkt532
   PubMed Web of Science ®Google Scholar
• Bousquet L, Pruvost A, Guyot AC, et al. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother. 2009 Mar;53(3):896–902. doi: 10.1128/AAC.00733-08
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52(9):3144–3160. doi: 10.1128/AAC.00350-08
   PubMed Web of Science ®Google Scholar
• Custodio JM, Fordyce M, Garner W, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-Uninfected subjects with severe renal impairment. Antimicrob Agents Chemother. 2016;60(9):5135–5140. doi: 10.1128/AAC.00005-16
   PubMed Web of Science ®Google Scholar
• Symtuza® summary of product characteristics. https://ec.europa.eu/health/documents/community-register/2017/20170921138687/anx_138687_en.pdf
   Google Scholar
• Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78(17):1817–1828. doi: 10.1007/s40265-018-1010-7
   PubMed Web of Science ®Google Scholar
• Europe Medicines Agency. Assessment Report. Symtuza®. [cited 2023 Jul19]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/symtuza-epar-public-assessment-report_en.pdf
   Google Scholar
• Crauwels HM, Baugh B, Van Landuyt E, et al. Bioequivalence of the once-daily single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide compared to combined intake of the separate agents and the effect of food on bioavailability. Clin Pharmacol Drug Dev. 2019;8(4):480–491. doi: 10.1002/cpdd.628.
   PubMed Web of Science ®Google Scholar
• Mills A, Crofoot G Jr, McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69(4):439–445. doi: 10.1097/QAI.0000000000000618.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018;32(11):1431–1442. doi: 10.1097/QAD.0000000000001817.
   PubMed Web of Science ®Google Scholar
• Orkin C, Eron JJ, Rockstroh J, et al. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2020;34(5):707–718. doi: 10.1097/QAD.0000000000002463
   PubMed Web of Science ®Google Scholar
• Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23–e34. doi: 10.1016/S2352-3018(17)30179-0.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Orkin C, Cunningham D, et al. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Res. 2019;170:104543. doi: 10.1016/j.antiviral.2019.104543
   PubMed Web of Science ®Google Scholar
• Lathouwers E, Wong EY, Brown K, et al. Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase III randomized AMBER and EMERALD trials. AIDS Res Hum Retroviruses. 2020;36(1):48–57. doi: 10.1089/AID.2019.0111
   PubMed Web of Science ®Google Scholar
• Lathouwers E, Weinsteiger S, Baugh B, et al. Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials. J Med Virol. 2021;93(6):3985–3990. doi: 10.1002/jmv.26721
   PubMed Web of Science ®Google Scholar
• Huhn GD, Wilkin A, Mussini C, et al. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1. HIV Res Clin Pract. 2020;21(6):151–167. doi: 10.1080/25787489.2020.1844520
   PubMed Web of Science ®Google Scholar
• Huhn GD, Crofoot G, Ramgopal M, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study. Clin Infect Dis. 2020;71(12):3110–3117. doi: 10.1093/cid/ciz1213.
   PubMed Web of Science ®Google Scholar
• Dunn K, Rogers R, Simonson RB, et al. Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis. HIV Res Clin Pract. 2021;22(2):55–61. doi: 10.1080/25787489.2021.1915652
   PubMedGoogle Scholar
• Dunn K, Baugh B, Bejou N, et al. Low incidence and brief duration of gastrointestinal adverse events with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) over 96 weeks: post hoc analyses of AMBER and EMERALD. J Int Assoc Provid AIDS Care. 2022;21:23259582221088202. doi: 10.1177/23259582221088202
   Google Scholar
• Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364–e372. doi: 10.1016/S2352-3018(19)30080-3
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072. doi: 10.1016/S0140-6736(17)32299-7
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–155. doi: 10.1016/S0140-6736(18)32462-0
   PubMed Web of Science ®Google Scholar
• Cabello-Úbeda A, Baeza AG, García JT, et al. Changes in quality of sleep, mood, and other neuropsychiatric symptoms after switching dolutegravir/lamivudine/abacavir to darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a randomized study of people with human immunodeficiency virus with poor sleep quality: GESIDA 10418. Open Forum Infect Dis. 2022;9(9):ofac345. doi: 10.1093/ofid/ofac345.
   PubMed Web of Science ®Google Scholar
• Emond B, Rossi C, Côté-Sergent A, et al. Weight change and predictors of weight change among patients initiated on darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide: a real-world retrospective study. J Health Econ Outcomes Res. 2021;8(1):88–98. doi: 10.36469/jheor.2021.2435
   PubMedGoogle Scholar
• Clay PG, Yuet WC, Moecklinghoff CH, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15(1):17. doi: 10.1186/s12981-018-0204-0
   PubMed Web of Science ®Google Scholar
• Crauwels HM, Osiyemi O, Zorrilla C, et al. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen. HIV Med. 2019;20(5):337–343. doi: 10.1111/hiv.12721
   PubMed Web of Science ®Google Scholar
• Schuettfort G, Cabello A, Cotter AG, et al. Reasons for choice of antiretroviral regimens in HIV patients presenting late for initial treatment in Europe. AIDS Patient Care STDS. 2021;35(4):110–115. doi: 10.1089/apc.2021.0011
   PubMed Web of Science ®Google Scholar